Comparative Pharmacology
Head-to-head clinical analysis: E E S versus ILOTYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S versus ILOTYCIN.
E.E.S. vs ILOTYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (E.E.S.) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis. It also exhibits prokinetic effects on the gastrointestinal tract via motilin receptor agonism.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking peptidyl transferase activity and preventing translocation of peptides.
250-500 mg every 6 hours orally or 15-20 mg/kg/day IV divided every 6 hours.
Erythromycin base (Ilotycin): 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day. For IV: 15-20 mg/kg/day continuous infusion or divided every 6 hours.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in patients with hepatic impairment; may be shorter in children.
Terminal elimination half-life is 1.5-2 hours in adults, prolonged to 4-6 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily hepatic (biliary) excretion of unchanged drug and active metabolites; approximately 15% of an oral dose is excreted unchanged in urine. The remainder is eliminated via feces as unchanged drug and metabolites.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-15% biliary/fecal elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic